metastasis associated 1 family member 3Genealiases: []
Q-omics provides the consensus-scored MTA3 profile across patient tissues and cancer cell-line models. MTA3 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, MTA3 is differentially expressed in 11, with the highest sampling consensus in LUAD. Additionally, MTA3 protein abundance shows 26,670 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LIHC, LUAD, and LSCC as cancer lineages where MTA3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTA3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTA3 survival associations across molecular data types. MTA3 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (2) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTA3 RNA expression–survival associations across cancer types. High MTA3 expression shows unfavorable associations in LIHC, ACC, KIRP, BLCA and CHOL, but favorable associations in LGG. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for MTA3 RNA expression.
This table summarizes MTA3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 8. The strongest signals are observed in LUAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for MTA3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTA3 shows lower tumor expression in THCA and higher tumor expression in LUAD, LIHC, HNSC, LUSC and BRCA. The LUAD box plot shows higher MTA3 RNA expression in tumor versus normal tissue (log2 FC = +0.950, t-test p < 0.001).
This table shows molecular features associated with MTA3 in patient tissues and cancer cell lines. In patient samples, MTA3 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, MTA3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BLOOD_Lymphoma.
